Ask AI
ProCE Banner Series

Improving Outcomes for Patients With High-Risk, HR-Positive/HER2-Negative Early Breast Cancer

Register now for this CME/CE/CPE-certified interactive workshop series on risk assessment and individualizing adjuvant therapy in HR-positive/HER2-negative early breast cancer! After the meeting, download the associated slideset and a patient resource, listen to a patient podcast, and read expert commentaries on HR+/HER2- EBC.

  ACPE
  | ACPE
  | AMA
  | ANCC
  | ANCC
Who Should Attend

This program is intended for oncologists, pharmacists, nurse practitioners, oncology nurses, and other healthcare professionals on the multidisciplinary team who care for patients with breast cancer.

All Events

Past Events

January

18

2023

Improving Outcomes for Patients With High-Risk, HR-Positive/HER2-Negative Early Breast Cancer

6:00 PM - 8:00 PM Eastern Time (ET)

In-person

Private Event -- Seidman Cancer Center

March

25

2023

Improving Outcomes for Patients With High-Risk, HR-Positive/HER2-Negative Early Breast Cancer

11:30 AM - 12:30 PM Pacific Time (PT)

In-person

Private Event | Vegas, Las Vegas, Nevada

March

29

2023

Improving Outcomes for Patients With High-Risk, HR-Positive/HER2-Negative Early Breast Cancer (Online Registration)

11:30 AM - 12:30 PM Central Time (CT)

Virtual

CCO Simulcast | Host Group, TX, Kyle, Texas

March

31

2023

Improving Outcomes for Patients With High-Risk, HR-Positive/HER2-Negative Early Breast Cancer

7:00 PM - 8:00 PM Eastern Time (ET)

In-person

Private Event, Garden City, New York

April

18

2023

Improving Outcomes for Patients With High-Risk, HR-Positive/HER2-Negative Early Breast Cancer

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

Private Event, Royal Oak, Michigan

April

21

2023

Improving Outcomes for Patients With High-Risk, HR-Positive/HER2-Negative Early Breast Cancer

4:00 PM - 5:00 PM Eastern Time (ET)

In-person

Quality Cancer Care Alliance (QCCA) | Session 1 - 4:00 PM, Atlanta, Georgia

April

21

2023

Improving Outcomes for Patients With High-Risk, HR-Positive/HER2-Negative Early Breast Cancer

5:00 PM - 6:00 PM Eastern Time (ET)

In-person

Quality Cancer Care Alliance (QCCA) | Session 2 - 5:00 PM, Atlanta, Georgia

April

24

2023

Improving Outcomes for Patients With High-Risk, HR-Positive/HER2-Negative Early Breast Cancer

4:00 PM - 5:00 PM Eastern Time (ET)

Virtual

Private Event | Brooklyn, Brooklyn, New York

April

27

2023

Improving Outcomes for Patients With High-Risk, HR-Positive/HER2-Negative Early Breast Cancer

7:30 AM - 8:30 AM Pacific Time (PT)

Virtual

Private Event, Post Falls, Idaho

May

09

2023

Improving Outcomes for Patients With High-Risk, HR-Positive/HER2-Negative Early Breast Cancer

4:00 PM - 5:00 PM Mountain Time (MT)

Virtual

Private Event, Rio Rancho, New Mexico

May

10

2023

Improving Outcomes for Patients With High-Risk, HR-Positive/HER2-Negative Early Breast Cancer

11:30 AM - 12:30 PM Central Time (CT)

Virtual

Private Event | Host Group Decatur, Decatur, Texas

May

16

2023

Improving Outcomes for Patients With High-Risk, HR-Positive/HER2-Negative Early Breast Cancer

6:30 PM - 7:30 PM Central Time (CT)

In-personVirtual

Private Event | Host Group at Maggiano's Little Italy, Crystal Lake, Illinois

May

24

2023

Improving Outcomes for Patients With High-Risk, HR-Positive/HER2-Negative Early Breast Cancer

6:30 PM - 7:30 PM Eastern Time (ET)

In-person

Private Event | Host Group at Brio, Plantation, Florida

June

09

2023

Improving Outcomes for Patients With High-Risk, HR-Positive/HER2-Negative Early Breast Cancer

11:30 AM - 12:30 PM Mountain Time (MT)

Virtual

Private Event | Virtual Group, Colorado Springs, Colorado

June

15

2023

Improving Outcomes for Patients With High-Risk, HR-Positive/HER2-Negative Early Breast Cancer

8:00 AM - 9:00 AM Eastern Time (ET)

Virtual

Private Event | Virtual Group, Bennington, Vermont

June

22

2023

Improving Outcomes for Patients With High-Risk, HR-Positive/HER2-Negative Early Breast Cancer

9:00 AM - 10:00 AM Mountain Time (MT)

Virtual

Private Event | Virtual Group, Goodyear, Arizona

June

28

2023

Improving Outcomes for Patients With High-Risk, HR-Positive/HER2-Negative Early Breast Cancer

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

Private Event | Host Group Towson, Towson, Maryland

July

21

2023

Improving Outcomes for Patients With High-Risk, HR-Positive/HER2-Negative Early Breast Cancer

6:00 AM - 7:00 AM Central Time (CT)

Virtual

Private Event | Host Group Birmingham, Birmingham, Alabama

July

26

2023

Improving Outcomes for Patients With High-Risk, HR-Positive/HER2-Negative Early Breast Cancer [Open Registration]

8:30 AM - 9:30 AM Eastern Time (ET)

Virtual

CCO Simulcast | Host Group Hendersonville, Hendersonville, North Carolina

August

01

2023

Improving Outcomes for Patients With High-Risk, HR-Positive/HER2-Negative Early Breast Cancer

5:00 PM - 6:00 PM Eastern Time (ET)

Virtual

Private Event | Virtual Group, Newport News, Virginia

August

08

2023

Improving Outcomes for Patients With High-Risk, HR-Positive/HER2-Negative Early Breast Cancer

6:30 PM - 7:30 PM Pacific Time (PT)

In-personVirtual

Private Event | Host Group WC Yacht, Walnut Creek, California

August

12

2023

Improving Outcomes for Patients With High-Risk, HR-Positive/HER2-Negative Early Breast Cancer

10:10 AM - 11:10 AM Central Time (CT)

In-person

Private Event | Host Group at Table 100, Flowood, Mississippi

September

07

2023

Improving Outcomes for Patients With High-Risk, HR-Positive/HER2-Negative Early Breast Cancer

8:00 AM - 9:00 AM Eastern Time (ET)

Virtual

Private Event | Host Group NJ, Elizabeth, New Jersey

September

09

2023

Improving Outcomes for Patients With High-Risk, HR-Positive/HER2-Negative Early Breast Cancer

4:00 PM - 5:00 PM Pacific Time (PT)

In-person

Private Event | Host Group at JW Marriott, Los Angeles, California

September

13

2023

Improving Outcomes for Patients With High-Risk, HR-Positive/HER2-Negative Early Breast Cancer

8:00 AM - 9:00 AM Eastern Time (ET)

Virtual

Private Event | Virtual Group GA, Canton, Georgia

Faculty

Topics

Welcome

Risk Assessment in HR-Positive/HER2-Negative Breast Cancer

• Video: A Patient’s Journey With Early-Stage HR-Positive/HER2-Negative Breast Cancer
• Molecular profiling: when to test, how to test, and which patients to test
• Case discussions

Individualizing Adjuvant Therapy for HR-Positive/HER2-Negative
Early-Stage Breast Cancer

• Novel therapies to improve outcomes for high-risk patients in the adjuvant setting
• Neoadjuvant therapy considerations
• Optimal sequencing of targeted therapy with ET and chemotherapy
• Clinical trial spotlight

Strategies for Promoting Adherence and Persistence to Oral CDK4/6 Inhibitors in Early-Stage Breast Cancer

• Proactive management of adverse events associated with CDK4/6 inhibitors
• Shared decision-making between HCPs and patients for decisions concerning targeted therapies
• HCP and patient responsibilities for oral adherence

Audience Question and Answer

Concluding Remarks

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.

CME/CE Info

Goal Statement
The goal of this educational curriculum is to improve the knowledge, competence, and performance of learners to optimally assess the risk of patients with HR-positive/HER2-negative early breast cancer and select optimal individualized therapy for those with higher-risk disease.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Incorporate the evidence on the current use of Ki67 as a predictive and prognostic biomarker into clinical practice
  • Identify patients with high-risk features who may benefit from the addition of CDK4/6 inhibitor therapy to endocrine therapy in the adjuvant setting
  • Foster collaborative discussions and workflows between the oncology multidisciplinary team and patients to guide personalized treatment planning for HR-positive/HER2-negative early breast cancer
  • Promote strategies to ensure optimal adherence and persistence to prescribed oral CDK4/6 inhibitors in patients with early-stage breast cancer
  • Manage adverse events associated with oral targeted therapy in the adjuvant setting for patients with HR-positive/HER2-negative breast cancer 

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-212-L01-P

Type of Activity: Knowledge

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC

Supported by an educational grant from Lilly

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191